Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for Post-Teriparatide Bone Loss in IOP
NCT02049866Phase 2Completed
- Start
- Nov 2014
- Primary completion
- Mar 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of denosumab in idiopathic osteoporosis (IO). Started Nov 2014; status: completed.
02
Drugs
denosumab
03
Conditions
idiopathic osteoporosis (IO)
Beyond the preview
Go deeper on NCT02049866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049866.